PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that Health Canada has granted marketing authorization for its Pegfilgrastim Injection, enabling ...
Armlupeg, a biosimilar to Neulasta, is approved for reducing febrile neutropenia in non-myeloid malignancy patients undergoing myelosuppressive chemotherapy. Lupin's FDA-approved facility in India ...
Lupin shares are in focus on Monday after the firm announced that it has received approval from the United States Food and Drug Administration (USFDA) for Armlupeg (pegfilgrastim-unne) 6 mg/0.6 ml ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results